Summary and Key Takeaways for First-Line EGFR-Mutant NSCLC With Brain Metastases

In closing, Dr. Rodriguez emphasizes that for patients who present with brain metastases, first-line treatment selection in EGFR-positive metastatic NSCLC requires weighing CNS efficacy, overall survival, tolerability, and the patient’s priorities, all framed as a shared decision-making conversation.

She summarizes the data: both the FLAURA2 regimen (osimertinib plus chemotherapy) and the MARIPOSA regimen (amivantamab plus lazertinib) show an OS advantage over osimertinib monotherapy and improved CNS efficacy. She notes that MARIPOSA reported a longer duration of response and used a more uniform intracranial monitoring schedule across the trial population, which informs how she interprets the CNS data.

Thank you for watching this Case-Based Peer Perspectives first-line treatment optimization in EGFR-positive metastatic NSCLC with brain metastases. Please subscribe to our e-newsletter for information on upcoming video series.